Radius Health Inc. (RDUS) Shares Down 2.2%
Radius Health Inc. (NASDAQ:RDUS) traded down 2.2% during mid-day trading on Wednesday . The company traded as low as $55.12 and last traded at $55.51, with a volume of 684,987 shares trading hands. The stock had previously closed at $56.73.
A number of equities research analysts have issued reports on the stock. HC Wainwright upped their price target on shares of Radius Health from $55.00 to $71.00 and gave the company a “buy” rating in a report on Wednesday. Jefferies Group restated a “hold” rating and set a $46.00 price target on shares of Radius Health in a report on Tuesday. Canaccord Genuity set a $85.00 price target on shares of Radius Health and gave the company a “buy” rating in a report on Monday. Zacks Investment Research cut shares of Radius Health from a “hold” rating to a “sell” rating in a report on Monday, August 8th. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $70.00 price target on shares of Radius Health in a report on Friday, August 5th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $63.51.
The stock has a 50-day moving average of $54.72 and a 200-day moving average of $40.96. The firm’s market capitalization is $2.45 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/radius-health-inc-rdus-shares-down-2-2.html
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.95) by $0.06. During the same quarter in the previous year, the company earned ($0.61) EPS. On average, equities research analysts expect that Radius Health Inc. will post ($3.95) EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in Radius Health by 27.9% in the second quarter. BlackRock Inc. now owns 2,852 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 623 shares in the last quarter. Fifth Third Bancorp boosted its position in shares of Radius Health by 6.2% in the second quarter. Fifth Third Bancorp now owns 3,421 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 201 shares during the last quarter. Opera Trading Capital purchased a new position in shares of Radius Health during the first quarter valued at approximately $138,000. Teacher Retirement System of Texas boosted its position in shares of Radius Health by 21.4% in the second quarter. Teacher Retirement System of Texas now owns 4,169 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 736 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in shares of Radius Health by 11.7% in the first quarter. Envestnet Asset Management Inc. now owns 5,100 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 535 shares during the last quarter. 99.91% of the stock is owned by hedge funds and other institutional investors.
About Radius Health
Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.